The Cost-Effectiveness of Tislelizumab Plus Chemotherapy for Locally Advanced or Metastatic Nonsquamous Non-Small Cell Lung Cancer

Objective: To investigate the cost-effectiveness of adding Chinese-developed anti-PD-1 antibody tislelizumab to first-line pemetrexed-platinum chemotherapy in (1) a study population of patients with locally advanced or metastatic nonsquamous non-small cell lung cancer (nsqNSCLC) and without known se...

Descripción completa

Detalles Bibliográficos
Autores principales: Luo, Xia, Zhou, Zhen, Zeng, Xiaohui, Liu, Qiao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9354466/
https://www.ncbi.nlm.nih.gov/pubmed/35935852
http://dx.doi.org/10.3389/fphar.2022.935581

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9354466/
https://www.ncbi.nlm.nih.gov/pubmed/35935852
http://dx.doi.org/10.3389/fphar.2022.935581

Ejemplares similares